Baer Investment Advisory LLC Makes New Investment in Tempus AI, Inc. $TEM

Baer Investment Advisory LLC bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 22,226 shares of the company’s stock, valued at approximately $1,005,000.

A number of other institutional investors also recently modified their holdings of TEM. Royal Bank of Canada increased its position in Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after acquiring an additional 17,359 shares during the period. Rhumbline Advisers bought a new stake in Tempus AI in the 1st quarter valued at about $116,000. Prudential Financial Inc. acquired a new position in shares of Tempus AI during the 2nd quarter worth approximately $276,000. Russell Investments Group Ltd. grew its position in shares of Tempus AI by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Tempus AI by 2,926.6% in the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock valued at $13,446,000 after buying an additional 204,629 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Insider Activity at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 4,116 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $181,392.12. Following the sale, the chief accounting officer owned 74,041 shares in the company, valued at $3,262,986.87. This represents a 5.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $57.48, for a total value of $9,556,050.00. Following the sale, the chief executive officer directly owned 8,775,283 shares of the company’s stock, valued at $504,403,266.84. This represents a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 572,759 shares of company stock worth $29,238,424 over the last quarter. 24.26% of the stock is owned by company insiders.

Tempus AI Price Performance

Tempus AI stock opened at $60.27 on Friday. The firm has a market cap of $10.82 billion, a P/E ratio of -35.04 and a beta of 3.46. The stock’s 50 day moving average is $50.48 and its 200 day moving average is $54.57. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) earnings per share. As a group, research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. HC Wainwright cut their price target on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Wolfe Research began coverage on Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Jefferies Financial Group started coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price for the company. Finally, Guggenheim reduced their target price on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.